Welcome to our dedicated page for Relay Therapeutics news (Ticker: RLAY), a resource for investors and traders seeking the latest updates and insights on Relay Therapeutics stock.
Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that regularly issues news about its small molecule programs for cancer and genetic disease. Company updates frequently highlight progress for its lead PI3Kα program, RLY-2608, also referred to as zovegalisib, and the use of its Dynamo® platform to address challenging protein targets.
Investors and followers of RLAY news can expect detailed announcements on clinical trial milestones, including interim and subset analyses from the ReDiscover first-in-human study and the Phase 3 ReDiscover-2 trial in HR+/HER2- breast cancer with PI3Kα mutations. Press releases have described efficacy measures such as progression-free survival and objective response rates, as well as safety and tolerability profiles for zovegalisib or RLY-2608 in combination with agents like fulvestrant and CDK inhibitors.
Relay Therapeutics also issues corporate and financial updates, such as quarterly financial results, cash runway commentary, and changes to its Board of Directors. These items are often accompanied by Form 8-K filings and may include information on research and development spending, general and administrative expenses, and net loss figures, without serving as investment advice.
Additional news items cover participation in healthcare and biotechnology investor conferences, where company management joins fireside chats hosted by firms such as Jefferies, Goldman Sachs, Wells Fargo, Guggenheim and Morgan Stanley. These events provide further context on strategy, the Dynamo platform, and the clinical pipeline, including programs for NRAS-driven solid tumors and Fabry disease.
This news page aggregates such disclosures so readers can follow Relay Therapeutics’ clinical progress, scientific presentations at meetings like ASCO and SABCS, and ongoing corporate developments related to the RLAY stock.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: the Cowen 3rd Annual Oncology Innovation Summit on June 2, 2022, at 11:30 a.m. ET and the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022, at 5:40 p.m. ET. Both events will be webcast live, accessible via Relay Therapeutics' website, and archived for 30 days post-event. The company focuses on precision medicines, integrating advanced computational and experimental technologies to enhance drug discovery in oncology and genetic disease.
Relay Therapeutics (Nasdaq: RLAY) reported its first quarter 2022 financial results, showing a net loss of $62.0 million or $0.57 per share, up from a net loss of $42.2 million in Q1 2021. As of March 31, 2022, the company held approximately $898 million in cash and equivalents, sufficient to support operations into 2025. Notable achievements include the initiation of the combination arm for RLY-2608 and continued enrollment for RLY-4008 expansion cohorts. The company anticipates releasing initial clinical data for RLY-2608 in H1 2023.
Relay Therapeutics (Nasdaq: RLAY) announced participation in a fireside chat at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 3:20 p.m. PT in Las Vegas, NV. The chat will be broadcast live via their website and can be accessed under the Events section. An archived replay will be available for 30 days post-event. Relay Therapeutics focuses on precision medicines, leveraging its Dynamo™ platform for drug discovery in oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) will announce its first quarter 2022 financial results and corporate highlights on May 5, 2022, after market close. The company is focused on transforming drug discovery through its innovative Dynamo™ platform, which leverages advanced computational and experimental technologies to target previously difficult-to-drug proteins. Relay Therapeutics aims to pioneer new small molecule therapies primarily for oncology and genetic diseases, potentially impacting patient outcomes significantly.
Relay Therapeutics (Nasdaq: RLAY) announced promising interim clinical data for RLY-4008, the first therapy targeting FGFR2, showing approximately 80% of patients with FGFR2-altered tumors achieved tumor size reductions. The company reported a net loss of $67.5 million for Q4 2021, with total cash and investments of $958.1 million as of December 31, 2021, expected to fund operations into at least 2025. Relay also presented preclinical data for RLY-2608, an innovative PI3Kα inhibitor, and outlined significant growth in R&D expenses due to increased clinical activities.
Relay Therapeutics (Nasdaq: RLAY) announced plans to release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. The company specializes in precision medicine, leveraging advanced computational and experimental technologies to enhance drug discovery. Notably, Relay Therapeutics utilizes its Dynamo™ platform to target challenging protein structures, focusing on therapies for oncology and genetic diseases. A teleconference will not be held alongside this press release.
Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming healthcare conferences. The first is a fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022, at 9:30 a.m. ET. Following this, Relay will join a panel discussion at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET. Both events will be webcast live, and viewers can access them via the Investors & Media page on Relay's website. Archived replays will be available for 30 days post-event.
Relay Therapeutics (Nasdaq: RLAY) has commenced a first-in-human trial for RLY-2608, a pan-mutant PI3Kα inhibitor, dosing its first patient with advanced solid tumors harboring PIK3CA mutations. Simultaneously, it has initiated expansion cohorts for RLY-4008, a selective FGFR2 inhibitor, targeting patients with FGFR2-altered cancers. Both trials aim to evaluate the drugs' safety, tolerability, and efficacy, expanding upon promising prior data. With a robust pipeline and strong financial position, the company is well-positioned to advance its clinical programs and address significant unmet medical needs.
Relay Therapeutics (Nasdaq: RLAY) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 9:45 a.m. ET. Interested parties can access the live webcast through the company's website, with an archived replay available for 30 days post-presentation. Relay Therapeutics specializes in precision medicine, utilizing its innovative Dynamo™ platform to advance drug discovery aimed at targeted oncology and genetic diseases.
Relay Therapeutics (Nasdaq: RLAY) presented promising preclinical data for RLY-2608, a novel allosteric PI3Kα inhibitor, at the 2021 San Antonio Breast Cancer Symposium. The data highlighted the compound's ability to synergize with standard therapies like fulvestrant and abemaciclib, leading to significant tumor regression in breast cancer models. RLY-2608 is designed to selectively target PIK3CA mutant tumors while minimizing toxicity. A first-in-human clinical trial is expected to commence in the first half of 2022, pending FDA approval.